EW
IRWD icon

Evoke Wealth’s Ironwood Pharmaceuticals IRWD Stock Holding History

Evoke Wealth’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.3K Buy
12,062
+775
+7% +$3.18K ﹤0.01% 705
2025
Q4 		$38K Buy
11,287
+452
+4% +$1.17K ﹤0.01% 679
2025
Q3 		$14.2K Buy
+10,835
New +$11.2K ﹤0.01% 650

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Evoke Wealth's IRWD Position: Q1 2026 in Review

Evoke Wealth increased its Ironwood Pharmaceuticals (IRWD) stake by 6.9% in Q1 2026, buying an estimated $3.18K and bringing the position to 12,062 shares worth $42.3K. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Evoke Wealth first reported a position in IRWD in Q3 2025 and has held it in 3 quarters since. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Evoke Wealth held 12,062 shares of Ironwood Pharmaceuticals worth $42.3K as of Q1 2026.
  • Evoke Wealth bought 775 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $3.18K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Evoke Wealth's portfolio in Q1 2026, its #705 holding.
  • Evoke Wealth first reported a position in Ironwood Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Evoke Wealth's 13F filing for Q1 2026, filed 15 May 2026.